CN101011584A - 获得持续的转基因表达的方法 - Google Patents

获得持续的转基因表达的方法 Download PDF

Info

Publication number
CN101011584A
CN101011584A CNA2007100787515A CN200710078751A CN101011584A CN 101011584 A CN101011584 A CN 101011584A CN A2007100787515 A CNA2007100787515 A CN A2007100787515A CN 200710078751 A CN200710078751 A CN 200710078751A CN 101011584 A CN101011584 A CN 101011584A
Authority
CN
China
Prior art keywords
nucleic acid
disease
expression
pulmonary
cys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007100787515A
Other languages
English (en)
Chinese (zh)
Inventor
P·卢
D·L·恩尼斯特
M·米纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN101011584A publication Critical patent/CN101011584A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CNA2007100787515A 1999-12-28 2000-12-27 获得持续的转基因表达的方法 Pending CN101011584A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47301899A 1999-12-28 1999-12-28
US09/473,018 1999-12-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB008186731A Division CN1310679C (zh) 1999-12-28 2000-12-27 获得持续的转基因表达的方法

Publications (1)

Publication Number Publication Date
CN101011584A true CN101011584A (zh) 2007-08-08

Family

ID=23877847

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB008186731A Expired - Fee Related CN1310679C (zh) 1999-12-28 2000-12-27 获得持续的转基因表达的方法
CNA2007100787515A Pending CN101011584A (zh) 1999-12-28 2000-12-27 获得持续的转基因表达的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CNB008186731A Expired - Fee Related CN1310679C (zh) 1999-12-28 2000-12-27 获得持续的转基因表达的方法

Country Status (8)

Country Link
EP (1) EP1242608A2 (de)
JP (1) JP2003522133A (de)
CN (2) CN1310679C (de)
AU (1) AU3164801A (de)
CA (1) CA2395544A1 (de)
IL (1) IL150485A0 (de)
NZ (1) NZ531527A (de)
WO (1) WO2001048231A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003223718B2 (en) * 2002-04-25 2007-08-16 The Scripps Research Institute Treatment and prevention of pulmonary conditions
CN101495498B (zh) * 2005-02-07 2013-09-18 基因信息公司 轻度骨关节炎生物标志物及其用途
US20070225233A1 (en) * 2006-03-27 2007-09-27 Tsu-Fuh Yeh Reducing the risk of chronic lung disease in infants
CN113384705A (zh) * 2021-06-28 2021-09-14 西南大学 泊洛沙姆修饰的脂质体的制备及在口服药物递送中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0465529B1 (de) * 1989-03-21 1998-04-29 Vical, Inc. Expression von exogenen polynukleotidsequenzen in wirbeltieren
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
EP1181937A3 (de) * 1994-08-09 2004-02-04 Cytrx Corporation Nukleinsäure enthaltender Impfstoff, Impfstoff-adjuvans
US5633227A (en) * 1994-09-12 1997-05-27 Miles, Inc. Secretory leukocyte protease inhibitor as an inhibitor of tryptase
EP0804076A4 (de) * 1994-10-19 1998-10-21 Genetic Therapy Inc Gentherapy durch gleichzeitige und wiederholte verabreichung von adenovirus und immunsuppresiven mitteln
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US6353055B1 (en) * 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
WO1996015780A1 (en) * 1994-11-23 1996-05-30 Isis Pharmaceuticals, Inc. Compositions and methods for preventing and treating allograft rejection
MY134778A (en) * 1995-10-23 2007-12-31 Hyal Pharmaceutical Australia Ltd Hyaluronic acid as dna carrier for gene therapy and vegf antisense dna to treat abnormal retinal vascularization
DE19711800A1 (de) * 1997-03-21 1998-09-24 Hoechst Ag Verlängerung der Expression von transgenen Proteinen durch immunmodulierende Behandlung
ATE321882T1 (de) * 1997-07-01 2006-04-15 Isis Pharmaceuticals Inc Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre

Also Published As

Publication number Publication date
CA2395544A1 (en) 2001-07-05
CN1310679C (zh) 2007-04-18
EP1242608A2 (de) 2002-09-25
NZ531527A (en) 2005-10-28
CN1433477A (zh) 2003-07-30
AU3164801A (en) 2001-07-09
WO2001048231A2 (en) 2001-07-05
IL150485A0 (en) 2002-12-01
JP2003522133A (ja) 2003-07-22
WO2001048231A3 (en) 2002-04-04

Similar Documents

Publication Publication Date Title
US20230293728A1 (en) Liver-Specific Nucleic Acid Regulatory Elements and Methods and Use Thereof
US20220273766A1 (en) Engineered nucleic acids and methods of use thereof
US20230414686A1 (en) Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
Brigham et al. Transfection of nasal mucosa with a normal alpha1-antitrypsin gene in alpha1-antitrypsin-deficient subjects: comparison with protein therapy
US6258791B1 (en) Combination product for enhanced gene delivery comprising a hyaluronidase
DK2790719T3 (en) Methods for preventing or treating certain diseases by inhibiting the binding of IL-4 and / or IL-13 to their respective receptors
WO2006076288A2 (en) Dna constructs for long-term expression of intravascularly injected naked dna
JP2021500341A (ja) 肺組織への標的化薬物及び遺伝子送達のためのシンシチンの使用
US20210260168A1 (en) Compositions and methods of fas inhibition
WO2020084162A1 (en) Liver-specific nucleic acid regulatory elements and methods and use thereof
AU732447B2 (en) Gene delivery and expression in areas inaccessible to direct protein delivery
CN101011584A (zh) 获得持续的转基因表达的方法
JP2022512974A (ja) 生体内ｃｒｉｓｐｒ超抑制因子による合成免疫調節
US7361639B2 (en) Gene therapy agent for Haemophilia B and its preparation method
US7074399B2 (en) Treatment of inflammation with p20
Colletti et al. Early fetal gene delivery utilizes both central and peripheral mechanisms of tolerance induction
US20030148975A1 (en) Method of achieving persistent transgene expression
AU2004240187A1 (en) Method of achieving persistent transgene expression
US20040071677A1 (en) Nephritis treatment by gene therapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication